RAPT Net Working Capital vs Capital Stock Analysis

RAPT Stock

USD 3.84 0.19 4.71%

RAPT Therapeutics financial indicator trend analysis is much more than just breaking down RAPT Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RAPT Therapeutics is a good investment. Please check the relationship between RAPT Therapeutics Net Working Capital and its Capital Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Net Working Capital vs Capital Stock

Net Working Capital vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RAPT Therapeutics Net Working Capital account and Capital Stock. At this time, the significance of the direction appears to have very strong relationship.

The correlation between RAPT Therapeutics' Net Working Capital and Capital Stock is 0.85. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Capital Stock in the same time period over historical financial statements of RAPT Therapeutics, assuming nothing else is changed. The correlation between historical values of RAPT Therapeutics' Net Working Capital and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of RAPT Therapeutics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Net Working Capital i.e., RAPT Therapeutics' Net Working Capital and Capital Stock go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Working Capital

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Most indicators from RAPT Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RAPT Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.At this time, RAPT Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 12.53 in 2024, whereas Selling General Administrative is likely to drop slightly above 14.6 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	996K	1.0M	1.1M	944.2K
Total Operating Expenses	73.0M	87.3M	123.5M	71.0M

Reconciled Depreciation Total Operating Expenses

RAPT Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.54	0.81	0.95	0.84	0.89	0.84	0.57	-0.85	0.77	-0.45	0.91	0.9	0.78	1.0	0.91	0.9	-0.75	0.89	0.83	0.95	-0.72	0.95	0.62	1.0	1.0
Other Current Liab	0.54		0.7	0.48	0.43	0.73	0.74	0.18	-0.84	0.78	-0.13	0.74	0.82	0.03	0.53	0.58	0.7	-0.4	0.77	0.35	0.64	-0.34	0.48	0.97	0.53	0.5
Total Current Liabilities	0.81	0.7		0.84	0.91	0.91	0.84	0.36	-0.92	0.95	-0.24	0.87	0.82	0.31	0.8	0.91	0.98	-0.78	0.91	0.82	0.93	-0.73	0.84	0.81	0.8	0.77
Total Stockholder Equity	0.95	0.48	0.84		0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.91	0.95	-0.9	1.0	0.62	0.95	0.94
Other Liab	0.84	0.43	0.91	0.89		0.89	0.68	0.47	-0.83	0.78	-0.39	0.73	0.72	0.45	0.83	0.89	0.92	-0.85	0.87	0.97	0.9	-0.82	0.89	0.59	0.84	0.81
Net Tangible Assets	0.89	0.73	0.91	0.87	0.89		0.78	0.46	-0.97	0.83	-0.4	0.84	0.93	0.44	0.89	0.89	0.95	-0.76	1.0	0.86	0.92	-0.72	0.87	0.83	0.89	0.87
Property Plant And Equipment Net	0.84	0.74	0.84	0.82	0.68	0.78		0.22	-0.82	0.86	-0.06	0.98	0.83	0.52	0.83	0.83	0.87	-0.69	0.8	0.66	0.87	-0.66	0.82	0.77	0.83	0.81
Net Debt	0.57	0.18	0.36	0.41	0.47	0.46	0.22		-0.42	0.42	-0.97	0.34	0.47	0.5	0.58	0.36	0.42	-0.15	0.45	0.41	0.51	-0.12	0.41	0.18	0.58	0.59
Retained Earnings	-0.85	-0.84	-0.92	-0.84	-0.83	-0.97	-0.82	-0.42		-0.9	0.35	-0.87	-0.95	-0.35	-0.84	-0.9	-0.95	0.75	-0.99	-0.77	-0.92	0.7	-0.84	-0.92	-0.84	-0.82
Accounts Payable	0.77	0.78	0.95	0.76	0.78	0.83	0.86	0.42	-0.9		-0.28	0.89	0.83	0.28	0.76	0.86	0.93	-0.67	0.85	0.66	0.91	-0.61	0.76	0.84	0.76	0.73
Cash	-0.45	-0.13	-0.24	-0.31	-0.39	-0.4	-0.06	-0.97	0.35	-0.28		-0.18	-0.39	-0.38	-0.47	-0.26	-0.3	0.1	-0.39	-0.35	-0.39	0.07	-0.31	-0.13	-0.47	-0.48
Non Current Assets Total	0.91	0.74	0.87	0.86	0.73	0.84	0.98	0.34	-0.87	0.89	-0.18		0.9	0.59	0.9	0.89	0.92	-0.69	0.86	0.68	0.93	-0.65	0.86	0.78	0.9	0.88
Non Currrent Assets Other	0.9	0.82	0.82	0.83	0.72	0.93	0.83	0.47	-0.95	0.83	-0.39	0.9		0.53	0.9	0.87	0.9	-0.65	0.95	0.67	0.9	-0.6	0.83	0.86	0.9	0.88
Other Assets	0.78	0.03	0.31	0.68	0.45	0.44	0.52	0.5	-0.35	0.28	-0.38	0.59	0.53		0.79	0.54	0.46	-0.4	0.42	0.5	0.59	-0.41	0.68	0.06	0.79	0.81
Cash And Short Term Investments	1.0	0.53	0.8	0.95	0.83	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79		0.9	0.89	-0.74	0.88	0.82	0.95	-0.71	0.95	0.61	1.0	1.0
Common Stock Total Equity	0.91	0.58	0.91	0.96	0.89	0.89	0.83	0.36	-0.9	0.86	-0.26	0.89	0.87	0.54	0.9		0.96	-0.89	0.9	0.85	0.98	-0.87	0.96	0.72	0.9	0.88
Common Stock Shares Outstanding	0.9	0.7	0.98	0.91	0.92	0.95	0.87	0.42	-0.95	0.93	-0.3	0.92	0.9	0.46	0.89	0.96		-0.81	0.95	0.84	0.98	-0.77	0.91	0.8	0.9	0.87
Non Current Liabilities Total	-0.75	-0.4	-0.78	-0.92	-0.85	-0.76	-0.69	-0.15	0.75	-0.67	0.1	-0.69	-0.65	-0.4	-0.74	-0.89	-0.81		-0.77	-0.89	-0.82	1.0	-0.92	-0.59	-0.75	-0.73
Capital Surpluse	0.89	0.77	0.91	0.87	0.87	1.0	0.8	0.45	-0.99	0.85	-0.39	0.86	0.95	0.42	0.88	0.9	0.95	-0.77		0.83	0.93	-0.72	0.87	0.87	0.88	0.86
Other Current Assets	0.83	0.35	0.82	0.91	0.97	0.86	0.66	0.41	-0.77	0.66	-0.35	0.68	0.67	0.5	0.82	0.85	0.84	-0.89	0.83		0.85	-0.88	0.91	0.53	0.83	0.81
Other Stockholder Equity	0.95	0.64	0.93	0.95	0.9	0.92	0.87	0.51	-0.92	0.91	-0.39	0.93	0.9	0.59	0.95	0.98	0.98	-0.82	0.93	0.85		-0.79	0.95	0.74	0.95	0.93
Total Liab	-0.72	-0.34	-0.73	-0.9	-0.82	-0.72	-0.66	-0.12	0.7	-0.61	0.07	-0.65	-0.6	-0.41	-0.71	-0.87	-0.77	1.0	-0.72	-0.88	-0.79		-0.9	-0.53	-0.72	-0.7
Net Invested Capital	0.95	0.48	0.84	1.0	0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.91	0.95	-0.9		0.62	0.95	0.94
Property Plant And Equipment Gross	0.62	0.97	0.81	0.62	0.59	0.83	0.77	0.18	-0.92	0.84	-0.13	0.78	0.86	0.06	0.61	0.72	0.8	-0.59	0.87	0.53	0.74	-0.53	0.62		0.61	0.58
Total Current Assets	1.0	0.53	0.8	0.95	0.84	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79	1.0	0.9	0.9	-0.75	0.88	0.83	0.95	-0.72	0.95	0.61		1.0
Net Working Capital	1.0	0.5	0.77	0.94	0.81	0.87	0.81	0.59	-0.82	0.73	-0.48	0.88	0.88	0.81	1.0	0.88	0.87	-0.73	0.86	0.81	0.93	-0.7	0.94	0.58	1.0

Click cells to compare fundamentals

RAPT Therapeutics Account Relationship Matchups

RAPT Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Other Current Liab	471K	328K	254K	8.7M	14.2M	14.9M
Total Current Liabilities	9.3M	11.7M	9.6M	14.2M	21.8M	11.7M
Total Stockholder Equity	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Other Liab	969K	2.2M	3.0M	2.7M	3.1M	2.2M
Net Tangible Assets	73.1M	104.2M	186.4M	245.2M	281.9M	296.0M
Property Plant And Equipment Net	3.7M	3.0M	2.7M	9.5M	7.7M	5.1M
Net Debt	(77.4M)	(24.9M)	(24.0M)	(30.0M)	(40.6M)	(42.6M)
Retained Earnings	(162.0M)	(214.8M)	(284.0M)	(367.9M)	(484.7M)	(460.4M)
Accounts Payable	1.1M	2.4M	2.0M	3.4M	5.2M	2.7M
Cash	77.4M	24.9M	24.0M	38.9M	47.5M	37.0M
Non Current Assets Total	4.1M	3.4M	5.7M	13.5M	11.5M	7.1M
Cash And Short Term Investments	77.4M	111.5M	189.7M	249.1M	158.9M	141.1M
Common Stock Shares Outstanding	21.8M	24.1M	27.4M	32.5M	38.3M	27.7M
Liabilities And Stockholders Equity	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Non Current Liabilities Total	2.2M	3.0M	2.7M	6.8M	4.5M	4.2M
Capital Surpluse	235.0M	319.2M	470.6M	613.1M	705.0M	740.3M
Other Current Assets	3.1M	4.1M	3.3M	3.6M	2.9M	3.0M
Other Stockholder Equity	150.4M	319.2M	470.6M	613.1M	631.6M	375.9M
Total Liab	11.5M	14.8M	12.3M	21.0M	26.3M	23.3M
Net Invested Capital	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Property Plant And Equipment Gross	3.7M	3.0M	2.7M	9.5M	17.0M	17.9M
Total Current Assets	80.5M	115.6M	193.0M	252.7M	161.8M	144.1M
Accumulated Other Comprehensive Income	20K	(177K)	(206K)	(26K)	103.0K	108.1K
Net Working Capital	71.3M	103.9M	183.4M	238.5M	139.9M	132.4M
Property Plant Equipment	3.7M	3.0M	2.7M	2.5M	2.3M	2.4M

Pair Trading with RAPT Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if RAPT Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RAPT Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against RAPT Stock

0.89	JPSTF	JAPAN POST BANK	Pair Corr
0.8	JPHLF	Japan Post Holdings	Pair Corr
0.74	PFE	Pfizer Inc Financial Report 6th of August 2024	Pair Corr
0.65	MESO	Mesoblast Fiscal Year End 4th of September 2024	Pair Corr
0.65	CRVS	Corvus Pharmaceuticals Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to RAPT Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace RAPT Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back RAPT Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling RAPT Therapeutics to buy it.

The correlation of RAPT Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as RAPT Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if RAPT Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for RAPT Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC